Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating

Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating

On Thursday, Sarepta Therapeutics got a positive adjustment to its Relative Strength (RS) Rating, from 77 to 84. This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against other publicly traded companies.